CN113777296A - Full-tissue immunofluorescence method and application - Google Patents
Full-tissue immunofluorescence method and application Download PDFInfo
- Publication number
- CN113777296A CN113777296A CN202111084317.4A CN202111084317A CN113777296A CN 113777296 A CN113777296 A CN 113777296A CN 202111084317 A CN202111084317 A CN 202111084317A CN 113777296 A CN113777296 A CN 113777296A
- Authority
- CN
- China
- Prior art keywords
- tissue
- triton
- pbs
- full
- immunofluorescence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010166 immunofluorescence Methods 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims abstract description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 15
- 210000002865 immune cell Anatomy 0.000 claims abstract description 14
- 230000010412 perfusion Effects 0.000 claims abstract description 13
- 238000009826 distribution Methods 0.000 claims abstract description 9
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 7
- 210000001519 tissue Anatomy 0.000 claims description 51
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 20
- 210000002569 neuron Anatomy 0.000 claims description 17
- 238000005406 washing Methods 0.000 claims description 15
- 241000699670 Mus sp. Species 0.000 claims description 11
- 210000002540 macrophage Anatomy 0.000 claims description 9
- 210000004761 scalp Anatomy 0.000 claims description 9
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims description 7
- 210000000115 thoracic cavity Anatomy 0.000 claims description 7
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 210000001562 sternum Anatomy 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 210000000683 abdominal cavity Anatomy 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000010791 quenching Methods 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 3
- -1 dye solution Chemical compound 0.000 claims description 3
- 210000005240 left ventricle Anatomy 0.000 claims description 3
- 229920002866 paraformaldehyde Polymers 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000003892 spreading Methods 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 239000005660 Abamectin Substances 0.000 claims description 2
- 206010002091 Anaesthesia Diseases 0.000 claims description 2
- 230000037005 anaesthesia Effects 0.000 claims description 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000012800 visualization Methods 0.000 claims 1
- 238000010186 staining Methods 0.000 abstract description 10
- 210000004204 blood vessel Anatomy 0.000 abstract description 8
- 238000003125 immunofluorescent labeling Methods 0.000 abstract description 8
- 210000005056 cell body Anatomy 0.000 abstract description 5
- 210000000601 blood cell Anatomy 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 3
- 239000010410 layer Substances 0.000 description 11
- 210000003238 esophagus Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 4
- 210000005216 enteric neuron Anatomy 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000005248 left atrial appendage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Abstract
The invention discloses a full-tissue immunofluorescence method and application, and belongs to the technical field of tissue immunofluorescence. The immunofluorescence method comprises the steps of obtaining the total tissue to be subjected to fluorescent staining, fixing the tissue overnight by formaldehyde fixing solution, and then carrying out immunofluorescence staining, wherein the total tissue is derived from an experimental mouse subjected to heart perfusion. According to the invention, the immunofluorescence staining is carried out on the whole amount of tissues obtained after the heart of the mouse is perfused, so that the residual blood cells in the blood vessel are effectively washed, the interference of nonspecific staining and immune cells in the blood vessel on staining results is reduced, the three-dimensional observation of the cells can be realized, the defects of inaccurate counting and inaccurate observation are avoided, and the problem that the traditional immunofluorescence staining cannot effectively observe and count the cells with sparse distribution and large cell bodies is solved.
Description
Technical Field
The invention belongs to the technical field of tissue immunofluorescence, and particularly relates to a full-tissue immunofluorescence method and application, which are particularly used for three-dimensionally observing the spatial distribution and counting of different cell populations in a tissue.
Background
The conventional mouse tissue immunofluorescence staining is based on tissue of a thin section (2-3 mu m), and the tissue quantity corresponding to the section is limited for the tissue with a small cross section (such as esophagus), so that the traditional method is difficult to effectively obtain a satisfactory staining result for cells with sparse distribution or large cell bodies, the section plane is usually difficult to capture the target cells, and the cells in the section plane cannot be effectively counted. In addition, for immune cells, non-specific staining of erythrocytes in blood vessels interferes with fluorescence, and the immune cells stained in blood vessels need to be eliminated, and the conventional method generally includes obtaining tissues after killing mice, and blood stagnation in blood vessels, which can not avoid the defects.
Disclosure of Invention
The invention mainly aims to provide a full-tissue immunofluorescence method, which can be used for effectively observing and counting cells with sparse distribution and large cell bodies in tissues by reducing the influence of blood cells in animal blood vessels on staining and obtaining the full-tissue after heart perfusion without slicing treatment.
The invention also aims to provide the application of the tissue immunofluorescence method in three-dimensional observation of cells.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a full-tissue immunofluorescence kit, which comprises a confining liquid, a cleaning liquid, a primary anti-diluent, a secondary anti-diluent, a DAPI (4', 6-diamidino-2-phenylindole) fluorescent dye and an anti-quenching confining tablet; wherein:
the blocking solution contained 10% BSA and 0.5% triton;
the cleaning solution is PBS solution containing 0.5% triton;
the primary antibody dilution was 5% BSA and 0.5% triton in PBS and the secondary antibody dilution was 2.5% BSA and 0.5% triton in PBS.
The invention provides an application of the full-tissue immunofluorescence kit in three-dimensional observation of gastrointestinal neurons or immunocytes.
Preferably, the gut enteric neuron is an esophageal enteric layer neuron, or the immune cell is a macrophage.
The invention also provides a full-tissue immunofluorescence method, which comprises the following steps:
(1) obtaining a total amount of tissues to be subjected to fluorescent staining, and fixing the tissues overnight by using 4% formaldehyde fixing solution;
(2) fluorescence staining of the total tissue: the fixed total tissue is subjected to fluorescent staining by the total tissue immunofluorescence kit, and the steps are as follows:
(a) washing with 0.5% triton-containing PBS for 30min for 3 times;
(b) blocking with blocking solution containing 10% BSA and 0.5% triton at room temperature for 2 hours;
(c) washing with 0.5% triton-containing PBS for 30min for 3 times;
(d) primary antibody was diluted with 5% BSA and 0.5% triton in PBS and incubated overnight at 4 degree freezer;
(e) washing with 0.5% triton-containing PBS for 30min for 3 times;
(f) the secondary antibody was diluted with 2.5% BSA and 0.5% triton in PBS and incubated at room temperature in the dark for 2 hours;
(g) washing with 0.5% triton-containing PBS for 30min for 3 times;
(h) incubating with DAPI, namely dye solution, at room temperature in dark for 20 min;
(i) washing with 0.5% triton-containing PBS for 30min for 3 times;
(j) taking out the whole treated tissue, spreading the tissue on a glass slide, drying the tissue in the air, dripping an anti-quenching sealing agent for sealing, and storing the tissue in a dark place;
wherein the total tissue is derived from experimental mice after cardiac perfusion.
Preferably, the full amount of tissue is gut neurons or immune cells.
Preferably, the method for obtaining the total amount of tissue comprises the steps of fixing, dissecting and perfusing the left ventricle of the mouse, and specifically comprises the following steps: the abdominal cavity of the mouse is injected with Avermectin with the dose of 20mg/kg for anesthesia, the four limbs of the mouse are fixed quickly after the mice take effect, the abdominal cavity is opened layer by layer, the diaphragm is opened after the sternum angle to enter the thoracic cavity, the thoracic cavity is opened to the two sides, the sternum angle is clamped by vascular forceps after the complete separation to be turned upwards, and the heart is exposed; inserting a scalp needle into the apex of the heart, fixing the scalp needle by the right hand to prevent slippage, cutting the right auricle by the left hand with an ophthalmological scissors, connecting the scalp needle with a 20ml syringe, slowly injecting 20ml of normal saline, continuously injecting 10ml of 4% paraformaldehyde after the color of the liver gradually changes from red to white, and ending the process.
The invention also provides the application of the full-tissue immunofluorescence method in cell three-dimensional observation.
Preferably, the cell is a gut enteric neuron or an immune cell.
More preferably, the gut enteric neuron is an esophageal enteric layer neuron and the immune cell is a macrophage.
Preferably, the cell stereotactic observation comprises observing the spatial distribution and count of different cell populations.
Compared with the prior art, the invention has the beneficial effects that:
(1) the full tissue immunofluorescence method of the invention carries out immunofluorescence staining on the full tissue after heart perfusion, utilizes the blood supply passage of the heart to tissue organs, and the physiological saline and the stationary liquid injected from the left ventricle can reach the tissue capillary, effectively washes the residual blood cells in the blood vessel, and reduces the interference of nonspecific staining and the immune cells in the blood vessel to the staining result.
(2) The invention utilizes the penetration of triton to carry out full-scale dyeing on the whole tissue, obtains target cells to the maximum extent, realizes the three-dimensional observation of the cells by confocal multilayer scanning, avoids the defects of inaccurate counting and inaccurate observation, and overcomes the problem that the traditional immunofluorescence dyeing can not effectively observe and count the cells with sparse distribution and larger cell bodies.
Drawings
Other features, objects and advantages of the invention will become more apparent upon reading of the detailed description of non-limiting embodiments with reference to the following drawings:
FIG. 1 is (a) conventional immunofluorescent staining of tissue sections: the rare neurons can be counted and can not be compared; (b) the invention comprises the following steps: neurons can be counted after stacking of multiple layers.
FIG. 2 is (a) conventional immunofluorescent staining of tissue sections: the macrophage has incomplete form and strong nonspecific staining; (b) the invention comprises the following steps: macrophage foot-bulge-like morphology.
FIG. 3 is a picture of the procedure for obtaining full-volume tissue by heart perfusion in experimental mice, wherein: (1) fixing; (2) dissecting; (3) indicating the left atrial appendage; (4) left ventricular perfusion; (5) the liver whitens after successful perfusion; (6) raising tail when pouring the fixing liquid.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention are clearly and completely described below with reference to the drawings of the embodiments of the present invention. It is to be understood that the embodiments described are only a few embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the described embodiments of the invention without any inventive step, are within the scope of protection of the invention.
The esophageal enteromyocyte neurons and macrophages are exemplified in the following examples.
Example 1
In this example, the whole tissue is obtained after heart perfusion of experimental mice (as shown in fig. 3), and the steps are as follows:
1. perfusion
On the 7 th day after the mice are administrated with tamoxifen, the mice are anesthetized by Abametin with the intraperitoneal injection dose of 20mg/kg, the limbs of the mice are fixed quickly after the mice take effect, the abdominal cavity is opened layer by layer, the diaphragm is opened from the back of the sternum angle, the thoracic cavity is entered into the thoracic cavity, the thoracic cavity is opened towards the two sides, and after full separation, the sternum angle is clamped by vascular clamps to be turned upwards to expose the heart. Inserting scalp needle into apex of heart, fixing scalp needle with right hand to prevent slippage, and cutting right auricle with left-hand ophthalmology scissors. The scalp needle is connected with a 20ml syringe, and 20ml of normal saline is injected slowly, so that the color of the liver gradually changes from red to white, and the effect of perfusion is indicated. After the normal saline is filled, 10ml of 4% paraformaldehyde is continuously filled, and the tail of the mouse is stiff and tilted at the moment, which indicates that the fixation is effective.
2. Taking materials
After the perfusion fixation is finished, the esophagus is found along the stomach, the esophagus is fully separated, and the esophagus and the stomach are cut off at the middle section and the stomach bottom of the esophagus respectively. Cleaning esophagus and stomach contents by using normal saline, longitudinally cutting a lumen, fixing the head end and the tail end by using pins, separating a muscular layer and a mucous layer from one end, wherein the muscular layer is soft and the mucous layer is relatively tough, tearing the muscular layer from the mucous layer along a longitudinal axis after finding out a tissue gap, and quickly putting the obtained muscular tissue into 4% formaldehyde fixing solution for fixing.
Example 2
Immunofluorescent staining was performed on the total amount of tissue obtained in example 1, as follows:
1) fixing with 4% formaldehyde fixing solution overnight, washing with 0.5% triton-containing PBS solution for 3 times, each for 30 min;
2) blocking with blocking solution containing 10% BSA and 0.5% triton at room temperature for 2 hours;
3) washing with 0.5% triton-containing PBS for 30min for 3 times;
4) diluting anti-mouse HuC/D and anti-mouse F4/80 with 5% BSA and 0.5% triton in PBS at a dilution ratio of 1: 400, 4 degree refrigerator incubation primary antibody overnight.
5) Washing with 0.5% triton-containing PBS for 30min for 3 times;
6) the anti-goat secondary-488 and anti-rat-Cy 3 were diluted with PBS solution containing 2.5% BSA and 0.5% triton at a dilution ratio of 1: 300. incubate for 2 hours at room temperature in the dark.
7) Washing with 0.5% triton-containing PBS for 30min for 3 times;
8) incubating with DAPI, namely dye solution, at room temperature in dark for 20 min;
9) washing with 0.5% triton-containing PBS for 30min for 3 times;
taking out the tissue, spreading the tissue on a glass slide, enabling the muscle to be parallel to the plane of the glass slide, drying the water in the air, dripping the anti-quenching sealing tablet, and storing the sealing tablet in the dark.
The manufactured full-fluorescence dyeing tissue slices are subjected to confocal multilayer scanning and fusion, and the method comprises the following steps: the secondary antibodies used for staining were switched on with corresponding lasers including 488, DAPI and Cy 3. First, the tissue piece is observed through an ocular lens, the dyeing condition is checked, and the position and the layer surface of the neuron are coarsely focused under the 488 laser condition. When observed in a 10-fold mirror preview mode, the slice is finely adjusted to a slice with high density distribution of both neurons and macrophages, and the slice is taken as the center, 10um upward is set as the upper bound, 10um downward is set as the lower bound, scanning is performed once every 1um, images are fused after scanning, and the number of neurons and the number of macrophages are counted, and the result is shown in fig. 1 and fig. 2.
In conclusion, the invention has the advantages over the traditional section staining when the histological research on the cells with sparse distribution and large cell bodies is required for the tissues with small cross sections of animals, and has use value for the research on digestive tract enteric neurons, immune cells and the like.
Claims (10)
1. A full-scale tissue immunofluorescence kit is characterized by comprising a confining liquid, a cleaning liquid, a primary anti-diluent, a secondary anti-diluent, a DAPI fluorescent dye and an anti-quenching confining tablet; wherein:
the blocking solution contained 10% BSA and 0.5% triton;
the cleaning solution is PBS solution containing 0.5% triton;
the primary antibody dilution was 5% BSA and 0.5% triton in PBS and the secondary antibody dilution was 2.5% BSA and 0.5% triton in PBS.
2. The use of the full-volume tissue immunofluorescence kit of claim 1 in the stereoscopic observation of gut neurons or immune cells.
3. The use of claim 2, wherein the gut-gut neurons are esophageal-gut myo-layer neurons and the immune cells are macrophages.
4. A full-tissue immunofluorescence method is characterized by comprising the following steps:
(1) obtaining a total amount of tissues to be subjected to fluorescent staining, and fixing the tissues overnight by using 4% formaldehyde fixing solution;
(2) the whole fixed tissue is subjected to fluorescent staining by the whole tissue immunofluorescence kit according to claim 1, and the steps are as follows:
(a) washing with 0.5% triton-containing PBS for 30min for 3 times;
(b) blocking with blocking solution containing 10% BSA and 0.5% triton at room temperature for 2 hours;
(c) washing with 0.5% triton-containing PBS for 30min for 3 times;
(d) primary antibody was diluted with 5% BSA and 0.5% triton in PBS and incubated overnight at 4 degree freezer;
(e) washing with 0.5% triton-containing PBS for 30min for 3 times;
(f) the secondary antibody was diluted with 2.5% BSA and 0.5% triton in PBS and incubated at room temperature in the dark for 2 hours;
(g) washing with 0.5% triton-containing PBS for 30min for 3 times;
(h) incubating with DAPI, namely dye solution, at room temperature in dark for 20 min;
(i) washing with 0.5% triton-containing PBS for 30min for 3 times;
(j) taking out the whole treated tissue, spreading the tissue on a glass slide, drying the tissue in the air, dripping an anti-quenching sealing agent for sealing, and storing the tissue in a dark place;
wherein the total tissue is derived from experimental mice after cardiac perfusion.
5. The method of claim 3, wherein the total tissue is gut neurons or immune cells.
6. The method of claim 5, wherein the gut neurons are esophageal gut layer neurons and the immune cells are macrophages.
7. The method for full-tissue immunofluorescence according to any one of claims 4 to 6, wherein the method for obtaining full-tissue comprises the steps of fixing, dissecting and left ventricle perfusion of the mouse, and specifically comprises the following steps: the abdominal cavity of the mouse is injected with Avermectin with the dose of 20mg/kg for anesthesia, the four limbs of the mouse are fixed quickly after the mice take effect, the abdominal cavity is opened layer by layer, the diaphragm is opened after the sternum angle to enter the thoracic cavity, the thoracic cavity is opened to the two sides, the sternum angle is clamped by vascular forceps after the complete separation to be turned upwards, and the heart is exposed; inserting a scalp needle into the apex of the heart, fixing the scalp needle by the right hand to prevent slippage, cutting the right auricle by the left hand with an ophthalmological scissors, connecting the scalp needle with a 20ml syringe, slowly injecting 20ml of normal saline, continuously injecting 10ml of 4% paraformaldehyde after the color of the liver gradually changes from red to white, and ending the process.
8. Use of the full-scale tissue immunofluorescence method of any one of claims 4 to 6 for the visualization of cell stereopsis.
9. The use of claim 8, wherein the cell is a gut neuron or an immune cell.
10. Use according to claim 8 or 9, wherein said cell stereoscopic observation comprises observing the spatial distribution and counting of said cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111084317.4A CN113777296A (en) | 2021-09-16 | 2021-09-16 | Full-tissue immunofluorescence method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111084317.4A CN113777296A (en) | 2021-09-16 | 2021-09-16 | Full-tissue immunofluorescence method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113777296A true CN113777296A (en) | 2021-12-10 |
Family
ID=78844430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111084317.4A Pending CN113777296A (en) | 2021-09-16 | 2021-09-16 | Full-tissue immunofluorescence method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113777296A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1307632A (en) * | 1998-06-25 | 2001-08-08 | 纽罗诺瓦股份公司 | Ependymal neural stem cells and method for their isolation |
| WO2006079036A2 (en) * | 2005-01-21 | 2006-07-27 | Northwestern University | Methods and compositions for encapsulation of cells |
| CN105556309A (en) * | 2013-09-20 | 2016-05-04 | 加州理工学院 | Methods for phenotyping of intact whole tissues |
| CN108139408A (en) * | 2015-08-07 | 2018-06-08 | 麻省理工学院 | Protein keeps extension microscopy |
| CN109679912A (en) * | 2019-03-05 | 2019-04-26 | 李海明 | A kind of isolated culture method of rat olfactory ensheathing cell |
| CN110763661A (en) * | 2018-07-25 | 2020-02-07 | 中国科学院合肥物质科学研究院 | Treatment fluid composition, kit and method for performing immunological labeling while transparentizing biological organ |
-
2021
- 2021-09-16 CN CN202111084317.4A patent/CN113777296A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1307632A (en) * | 1998-06-25 | 2001-08-08 | 纽罗诺瓦股份公司 | Ependymal neural stem cells and method for their isolation |
| WO2006079036A2 (en) * | 2005-01-21 | 2006-07-27 | Northwestern University | Methods and compositions for encapsulation of cells |
| CN105556309A (en) * | 2013-09-20 | 2016-05-04 | 加州理工学院 | Methods for phenotyping of intact whole tissues |
| CN108139408A (en) * | 2015-08-07 | 2018-06-08 | 麻省理工学院 | Protein keeps extension microscopy |
| CN110763661A (en) * | 2018-07-25 | 2020-02-07 | 中国科学院合肥物质科学研究院 | Treatment fluid composition, kit and method for performing immunological labeling while transparentizing biological organ |
| CN109679912A (en) * | 2019-03-05 | 2019-04-26 | 李海明 | A kind of isolated culture method of rat olfactory ensheathing cell |
Non-Patent Citations (1)
| Title |
|---|
| 曾雅琳 等: "PD1 经上调心脏巨噬细胞GPR37 /JNK/PPAR-γ 通路活性减轻大鼠心脏缺血再灌注损伤", 《第三军医大学学报》, pages 1511 - 1518 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101495049B (en) | Thorascopic heart valve repair method and apparatus | |
| Montgomery et al. | Embryonic development of the light organ of the sepiolid squid Euprymna scolopes Berry | |
| McCulloch | The zonule of Zinn: its origin, course, and insertion, and its relation to neighboring structures | |
| Anderson et al. | Renal morphology of freshwater trout | |
| CN107224617A (en) | A kind of hydrogel using spleen cell epimatrix as raw material and preparation method thereof | |
| CN107076724A (en) | Organism coloring agent | |
| SHIMADA et al. | Morphological studies of the cardiac lymphatic system | |
| Collado et al. | Pristina silvicola and Pristina terrena spp. nov., two new soil-dwelling species of Naididae (Oligochaeta, Annelida) from the tropical rain forest near Manaus, Brazil, with comments on the genus Pristinella | |
| Kille | Regeneration in Thyone briareus Lesueur following induced autotomy | |
| CN113777296A (en) | Full-tissue immunofluorescence method and application | |
| Pappenheimer | THE GOLGI APPARATUS PERSONAL OBSERVATIONS AND A REVIEW OF THE LITERATURE | |
| CN107970436A (en) | The modeling method of new vessels in new zealand white rabbit atherosclerotic plaque in abdominal aorta in model | |
| CN113713123B (en) | Fluorescent conjugated polymer nano-probe for imaging brain lymphatic system and blood vessels | |
| Suzuki et al. | Development of the bitterling Rhodeus uyekii (Cyprinidae), with a note on minute tubercles on the skin surface | |
| CN108653334A (en) | The human pluripotent stem cells excretion body for loading resveratrol is preparing the purposes reversed in organ senescence drug | |
| CN104141012B (en) | SH2B adaptin 1(SH2B1) at the function and application for the treatment of in myocardial hypertrophy | |
| Eastman | Aspects of the morphology of phyletically basal bovichtid fishes of the Antarctic suborder Notothenioidei (Perciformes) | |
| Lankester | Observations on the development of the Cephalopoda | |
| CN111345917A (en) | Myocardial injection molding method and device after myocardial infarction of mouse | |
| CN111642464A (en) | Animal model construction method for transplant vein restenosis research | |
| Axelsson | The demonstration of the cochlear vessels in the guinea pig by contrast injection | |
| CN111195254B (en) | LPA2 and use of agonists thereof | |
| CN113855650B (en) | Immune metabolism myocardial infarction patch and preparation method and application thereof | |
| CN110339361B (en) | Application of CUGBP1 protein or coding gene thereof in preparation of heart injury repair product | |
| Braun et al. | A handbook of practical parasitology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |